Tata Nifty MidSmall Healthcare Index Fund
The scheme seeks to provide returns, before expenses, that are in line with the performance of Nifty MidSmall Healthcare Index (TRI), subject to tracking error.
Growthvine rating: 1/5 — ranked #242 of 245 in category.
Fund basics
| Category | Equity: Index |
|---|
| NAV | ₹14.73 (as of 2026-10-01) |
|---|
| AUM | ₹219 Cr |
|---|
| Expense ratio | 0.90% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Nitin Bharat Sharma |
|---|
| Exit load | 0.25% for redemption within 15 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −17.62% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Market cap allocation
| Large cap | 0.0% |
|---|
| Mid cap | 67.5% |
|---|
| Small cap | 32.5% |
|---|
Concentration
| Top 5 holdings | 39.1% |
|---|
| Top 10 holdings | 60.0% |
|---|
| Total holdings | 30 |
|---|
Top holdings
- Laurus Labs Limited — 11.2%
- Lupin Ltd — 8.0%
- Aurobindo Pharma Ltd. — 7.2%
- Fortis Healthcare Ltd — 7.1%
- Glenmark Pharmaceuticals ltd — 5.6%
- Alkem Laboratories Limited — 4.7%
- Biocon Ltd. — 4.4%
- Ipca Laboratories Ltd. — 4.1%
- Mankind Pharma Limited — 4.1%
- Gland Pharma Limited — 3.5%
Top sectors
- Pharma & Biotech — 78.9%
- Healthcare — 21.3%
- Cash — −0.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 15.5% | — | — |
| 2025 | −1.5% | — | — |